Africa Eastern and Southern vs Namibia: Antiretroviral therapy coverage
Africa Eastern and Southern
83.9%
in 2024
Namibia
95.0%
in 2024
Africa Eastern and Southern rank
4th
Namibia rank
3rd
Antiretroviral therapy coverage over time
- Africa Eastern and Southern
- Namibia
How they compare
Namibia currently reports 95.0% against 83.9% in Africa Eastern and Southern, a difference of 11.1%.
That makes Namibia's figure about 1.1 times Africa Eastern and Southern's.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Africa Eastern and Southern ahead.
Africa Eastern and Southern ranks 4th and Namibia ranks 3rd of 23 groups.
Namibia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Africa Eastern and Southern | Namibia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 6.0% | 11.8% | 5.8% | Namibia |
| 2010s | 49.5% | 59.6% | 10.1% | Namibia |
| 2020s | 79.0% | 88.8% | 9.8% | Namibia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage, Africa Eastern and Southern or Namibia?
- Namibia, at 95.0% against 83.9% in Africa Eastern and Southern as of 2024.
- What is the difference in antiretroviral therapy coverage between Africa Eastern and Southern and Namibia?
- 11.1%, with Namibia ahead.
- How many years of comparable data are there for Africa Eastern and Southern and Namibia?
- 25 years are reported by both, from 2000 to 2024.
- How do Africa Eastern and Southern and Namibia rank globally for antiretroviral therapy coverage?
- Africa Eastern and Southern ranks 4th and Namibia ranks 3rd of 23 groups.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage (% of people living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.